“Tralokinumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis in Patients Aged 12 years and Older With and Without Atopic Comorbidities”, J of Skin, vol. 8, no. 1, p. s322, Jan. 2024, doi: 10.25251/skin.8.supp.322.